Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 6/20 | 0.58 |
| ▸ | MMP2 | P08253 | 5/20 | 0.58 |
| ▸ | MMP8 | P22894 | 4/20 | 0.58 |
| ▸ | MMP13 | P45452 | 4/20 | 0.58 |
| ▸ | BMP1 | P13497 | 7/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2516138 | 1.00 | MMP9 (0.58) | MMP9MMP2MMP8MMP13BMP1 | |
| SCHEMBL2857985 | 0.92 | MMP9 (0.56) | MMP9MMP2MMP8MMP13BMP1 | |
| SCHEMBL2857990 | 0.92 | MMP9 (0.56) | MMP9MMP2MMP8MMP13BMP1 | |
| SCHEMBL2859077 | 0.90 | MMP2 (0.61) | MMP9MMP2MMP8MMP13BMP1 | |
| SCHEMBL2859082 | 0.90 | MMP2 (0.61) | MMP9MMP2MMP8MMP13BMP1 | |
| SCHEMBL2857070 | 0.89 | MMP2 (0.61) | MMP9MMP2MMP8MMP13BMP1 | |
| SCHEMBL2857066 | 0.89 | MMP2 (0.61) | MMP9MMP2MMP8MMP13BMP1 | |
| SCHEMBL2853986 | 0.89 | MMP2 (0.53) | MMP9MMP2MMP8MMP13BMP1 | |
| SCHEMBL2853988 | 0.89 | MMP2 (0.53) | MMP9MMP2MMP8MMP13BMP1 | |
| SCHEMBL2858314 | 0.85 | BMP1 (0.58) | MMP9MMP2MMP8MMP13BMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2085379-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | Novartis AG (CH) | 2009-08-05 | — | — | EP | claimed |
| CN-1215055-C | Arylsulfonylamino-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | claimed |
| CN-1368958-A | Arylsulfonamido-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2002-09-11 | — | — | CN | claimed |
| EP-1202961-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | Novartis AG (CH) | 2002-05-08 | — | — | EP | claimed |
| WO-2001010827-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2001-02-15 | — | — | WO | claimed |
| US-8034810-B2 | Matrix metalloproteinase inhibitors; antiinflammatory agengs; rheumatoid arthritis, osteoarthritis; antitumor, anticarcinogenic, and antimetastasis agents; respiratory system disorders, chronic obstructive pulmonary disease, deblocking, deprotecting | NOVARTIS AG (CH) | 2011-10-11 | — | — | US | disclosed |
| US-8034810-B2 | Matrix metalloproteinase inhibitors; antiinflammatory agengs; rheumatoid arthritis, osteoarthritis; antitumor, anticarcinogenic, and antimetastasis agents; respiratory system disorders, chronic obstructive pulmonary disease, deblocking, deprotecting | NOVARTIS AG (CH) | 2011-10-11 | — | — | US | disclosed |
| US-8034810-B2 | Matrix metalloproteinase inhibitors; antiinflammatory agengs; rheumatoid arthritis, osteoarthritis; antitumor, anticarcinogenic, and antimetastasis agents; respiratory system disorders, chronic obstructive pulmonary disease, deblocking, deprotecting | NOVARTIS AG (CH) | 2011-10-11 | — | — | US | disclosed |
| EP-1202961-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| EP-1202961-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| EP-2085379-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | Novartis AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| EP-2085379-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | Novartis AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| US-20080275127-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | BREITENSTEIN WERNER | 2008-11-06 | — | — | US | disclosed |
| US-20080275127-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | BREITENSTEIN WERNER | 2008-11-06 | — | — | US | disclosed |
| US-20080275127-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | BREITENSTEIN WERNER | 2008-11-06 | — | — | US | disclosed |
| US-7138432-B1 | Arylsulfonamido-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2006-11-21 | — | — | US | disclosed |
| CN-1215055-C | Arylsulfonylamino-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | disclosed |
| CN-1368958-A | Arylsulfonamido-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2002-09-11 | — | — | CN | disclosed |
| EP-1202961-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | Novartis AG (CH) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010827-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275127-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | MMP13, MMP2, MMP1 | MMP9 10/4885MMP2 2/4885MMP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.